PMID- 19793712
OWN - NLM
STAT- MEDLINE
DCOM- 20091228
LR  - 20211203
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 13
IP  - 5
DP  - 2009 Oct
TI  - Targeting the mTOR pathway in neuroendocrine tumors.
PG  - 558-63
LID - 10.1188/09.CJON.558-563 [doi]
AB  - Neuroendocrine tumors (NETs) are rare, generally indolent tumors that are lethal 
      in the metastatic setting. Treatment options to control tumor growth are limited. 
      In clinical trials, investigational oral mammalian target of rapamycin (mTOR) 
      inhibitors have shown activity in patients with metastatic NETs. The purpose of 
      this article is to provide oncology nurses with a background on the mechanism of 
      action of mTOR inhibitors in the setting of NETs. Increased understanding of the 
      role of mTOR in the pathogenesis of NETs has led to the study of mTOR inhibitor 
      investigational agents in NETs. Treatments are evolving and currently focusing on 
      targeted agents such as mTOR inhibitors. Understanding the mechanisms of action 
      of targeted agents is a critical component of nursing knowledge.
FAU - Gardner, Nancy
AU  - Gardner N
AD  - Robert Wood Johnson University Hospital, and School of Nursing, Rutgers 
      University, Newark, NJ, USA. nancymgardner@msn.com
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Neuroendocrine/*drug therapy/metabolism/nursing
MH  - Humans
MH  - Protein Kinases/*drug effects
MH  - TOR Serine-Threonine Kinases
EDAT- 2009/10/02 06:00
MHDA- 2009/12/29 06:00
CRDT- 2009/10/02 06:00
PHST- 2009/10/02 06:00 [entrez]
PHST- 2009/10/02 06:00 [pubmed]
PHST- 2009/12/29 06:00 [medline]
AID - P77153Q328801X18 [pii]
AID - 10.1188/09.CJON.558-563 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2009 Oct;13(5):558-63. doi: 10.1188/09.CJON.558-563.